Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JZP150 · 1 trial · 1 indication
Clinician Administered Posttraumatic Stress Disorder (PTSD) Scale (CAPS-5) is a clinician administered, clinical interview where participants report on their symptoms of PTSD on a scale. The CAPS-5 total score ranges between 0 and 80. Higher scores indicate more severe PTSD symptoms. Change in CAPS-5 total score is being reported, where negative mean scores indicate an improvement in clinical outcome.
| Arm | Type | Description |
|---|---|---|
| JZP150 0.3 mg | EXPERIMENTAL | Participants who will be randomized to receive JZP150 0.3 mg orally once daily for up to 12 weeks. |
| JZP150 4.0 mg | EXPERIMENTAL | Participants who will be randomized to receive JZP150 4.0 mg orally once daily for up to 12 weeks. |
| Placebo | PLACEBO_COMPARATOR | Participants who will be randomized to receive placebo orally once daily for up to 12 weeks. |
| Name | Type | Description |
|---|---|---|
| JZP150 | DRUG | Oral administration of JZP150 once daily in the morning |
| Placebo | DRUG | Oral administration of placebo once daily in the morning |
Inclusion Criteria: * Participants aged 18 to 70 years * Participants must be outpatients with a primary diagnosis of Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) defined PTSD confirmed by the clinical interview * PTSD is primary diagnosis Exclusion Criteria: * Acute...
JZP150 is an investigational small molecule being developed for the treatment of post traumatic stress disorder (PTSD) in adults. It is a Phase 2 clinical-stage candidate from Jazz Pharmaceuticals plc and has been studied in a placebo-controlled trial in adults aged 18 years and older with PTSD.
JZP150 targets fatty acid amide hydrolase (FAAH), an enzyme. By acting on FAAH, JZP150 is designed to modulate the endocannabinoid system, which is being explored as a therapeutic approach in post traumatic stress disorder. FAAH is the only molecular target identified for JZP150.
JZP150 is being developed by Jazz Pharmaceuticals plc, which trades on Nasdaq under the ticker JAZZ. The company is the sponsor behind the Phase 2 clinical program evaluating JZP150 in adults with post traumatic stress disorder.
JZP150 is in Phase 2 clinical development for post traumatic stress disorder. It is an investigational therapy and is not approved for any indication. Its Phase 2 trial in adults with PTSD has been completed, and no trials of JZP150 are currently active.
JZP150 has been evaluated in one clinical trial, NCT05178316, titled A Study of JZP150 in Adults With Posttraumatic Stress Disorder. This completed Phase 2 trial enrolled 282 adults aged 18 and older in the United States. It was randomized, double blind, and placebo controlled, and did not include healthy volunteers.